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A loss of FUS/TLS function leads to impaired cellular
proliferation
CL Ward1, KJ Boggio1, BN Johnson2, JB Boyd2, S Douthwright3, SA Shaffer4,5, JE Landers1, MA Glicksman2 and DA Bosco*,1,4
Fused in sarcoma/translocated in liposarcoma (FUS/TLS or FUS) is a multifunctional RNA/DNA-binding protein that is
pathologically associated with cancer and neurodegeneration. To gain insight into the vital functions of FUS and how a loss of FUS
function impacts cellular homeostasis, FUS expression was reduced in different cellular models through RNA interference. Our
results show that a loss of FUS expression severely impairs cellular proliferation and leads to an increase in phosphorylated
histone H3, a marker of mitotic arrest. A quantitative proteomics analysis performed on cells undergoing various degrees of FUS
knockdown revealed protein expression changes for known RNA targets of FUS, consistent with a loss of FUS function with
respect to RNA processing. Proteins that changed in expression as a function of FUS knockdown were associated with multiple
processes, some of which influence cell proliferation including cell cycle regulation, cytoskeletal organization, oxidative stress and
energy homeostasis. FUS knockdown also correlated with increased expression of the closely related protein EWS (Ewing’s
sarcoma). We demonstrate that the maladaptive phenotype resulting from FUS knockdown is reversible and can be rescued by
re-expression of FUS or partially rescued by the small-molecule rolipram. These results provide insight into the pathways and
processes that are regulated by FUS, as well as the cellular consequences for a loss of FUS function.
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Fused in sarcoma/translocated in liposarcoma, FUS/TLS
(or FUS), is a member of the TET family of proteins that
also includes Ewing’s sarcoma (EWS) and TATA-binding
protein-associated factor 15 (TAF15). TET proteins carry out
RNA/DNA-processing activities in the context of diverse
cellular functions.1 FUS is predominately expressed in the
nucleus where it functions in transcription, splicing and DNA
damage repair and also shuttles to the cytoplasm, where it
has been found in translationally active RNA/protein foci, as
well as stress granules formed in response to osmotic
stress.2,3
FUS is also associated with several human diseases. FUS
was originally discovered in the context of an onco-fusion
protein that causes malignant myxoid liposarcoma. The
N-terminal transcriptional activation domain of FUS is fused
to the transcription factor CHOP, forming FUS-CHOP,4,5 which
accounts for490% of myxoid liposarcoma cases.6 Similarly,
fusion of FUS with either the transcription factor ERG or FEV
has been found in some cases of EWS family tumors7,8 or
acute myeloid leukemia,9,10 and fusion with ATF1 and either
CREB3 L2 or CREB3 L1 will cause angiomatoid fibrous
histiocytoma11 and low-grade fibromyxoid sarcoma,12
respectively. FUS also has a strong link to neurodegenerative
disorders such as amyotrophic lateral sclerosis (ALS),13,14
different subtypes of frontotemporal lobar degeneration15–19
and polyglutamine diseases such as Huntington’s disease
and spinocerebellar ataxia.20,21 The pathological role
of FUS in these disorders has not been elucidated, although
the observation that FUS is depleted from the nucleus and/or
becomes sequestered into aggregates within neurons and
glia during the course of neurodegeneration is consistent
with a mechanism involving a loss of FUS function.15,22,23
A role for a loss of FUS function in the context of essential
tremor, an adult-onset movement disorder, has also been
proposed.24–26
To study the cellular impact of FUS depletion, we
developed cellular models of FUS knockdown and
discovered FUS to be critical for homeostasis. Knockdown
of FUS in both human embryonic kidney 293T (HEK-293T)
and neuronal NSC-34 cells caused a significant defect in
cellular proliferation. Importantly, the proliferation defect
induced by FUS depletion is reversible, as both
re-expression of FUS and treatment with rolipram, a
phosphodiesterase-4 inhibitor that suppresses oxidative
stress, ameliorated this phenotype. A quantitative proteo-
mics analysis revealed various proteins that changed as a
function of FUS knockdown, including some that correspond
to known RNA-binding targets of FUS. The proteins and
pathways uncovered herein not only define the cellular
consequences of FUS depletion, but also serve as potential
therapeutic targets for ameliorating adverse phenotypes
arising from a loss of FUS function.
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Results
Cell number and viability directly correlate with FUS
protein expression. To investigate the cellular conse-
quences of a loss of FUS function, FUS expression was
knocked down in both murine NSC-34 (neuroblastoma ´
spinal cord hybrid 34) and HEK-293T cells. NSC-34 cells are
motor neuron-like27 and were utilized in light of the involve-
ment of FUS in neurodegeneration,3 whereas HEK-293T
cells were chosen as a suitable human cell line for in vitro
experiments. NSC-34 cell lines stably expressed tetracycline-
inducible shRNA specific for FUS (shFUS1 and shFUS2;
Figure 1a) or a scrambled shRNA control (shSC).2 After
shFUS induction for 4 days, FUS expression was knocked
down ~95% (Figure 1b). In addition, siRNA targeting the
3’UTR of FUS (Figure 1a) or a scrambled siRNA control was
used. Transient transfection of 3’UTR siRNA (si3’UTR) for
4 days resulted in ~ 85% knockdown of FUS in HEK-293T
cells (Figure 1b). Cell viability as determined by the MTT
assay was reduced 40–50% in NSC-34 cells expressing
shFUS and in HEK-293T cells expressing si3′UTR relative to
controls (Figure 1c). However, transient transfection of siRNA
was less efficient in NSC-34 cells (Figure 1d), resulting in
only ~ 55% FUS knockdown (Figure 1b) and ~ 15% decrease
in cell viability relative to the control (Figure 1c). A reduction in
viability (~20%) was also observed in control conditions,
likely due to the toxicity associated with transient transfec-
tion, continuous shRNA production and/or doxycycline
exposure.28 Nonetheless, these data demonstrate a reduc-
tion in cell viability resulting from FUS knockdown, achieved
by targeting several unique sequences within FUS in two
different cell lines.
To further investigate the relationship between FUS
expression and cellular homeostasis, we quantified cell
number and viability as a function of FUS depletion over time
using the inducible shFUS1 NSC-34 cell line (unless other-
wise noted, this linewas used for all subsequent experiments).
With continuous induction of shFUS, FUS protein levels
gradually decreased over time relative to uninduced cells and
remained low for 10 days (Figure 2a). Uninduced cells
exhibited an exponential growth rate with a 3.5- to 4-fold
increase in cell number every 2 days, whereas this growth rate
decreased to 2-fold in cells subjected to continuous FUS
knockdown (Figure 2b). Plotting cellular viability as a function
of FUS expression further demonstrates the direct correlation
between FUS expression and cellular homeostasis
(Figure 2c). The induction of shFUS was halted after 24 h in
a ‘wash-out’ experiment, wherein FUS levels returned to
baseline within 6 days (Figure 2a). It is noted that tetracycline
was used to induce shFUS in these experiments, as the wash-
out is ineffective with doxycycline (data not shown). Interest-
ingly, re-expression of FUS rescued the proliferation defect;
the rate of cell growth was the same in shFUS cells under the
wash-out condition as uninduced cells between days 8 and 10
(Figure 2b). Therefore, the adverse effects of FUS knockdown
are reversible.
Apoptosis is not activated during the cellular response to
FUS knockdown. Several factors influence proliferation
rate: the rate of cell division, the percentage of cells
Figure 1 FUS knockdown causes a reduction in cell viability. (a) FUS was targeted for knockdown by doxycycline induction of stably expressed shRNA directed at non-
overlapping regions in exon 5 (shFUS1, shFUS2) or by transient transfection of siRNA targeting the 3’UTR of either the human or mouse FUS sequence. (b) Western blot
analyses of the indicated cell lysate derived from FUS knockdown experiments. After 4 days of shFUS induction in NSC-34 cells (top) or transient transfection of 3’UTR FUS
siRNA in HEK-293T cells (bottom left), FUS expression was reduced by ~ 95% and ~ 85%, respectively, compared with controls. A less efficient FUS knockdown of ~ 55% was
observed for NSC-34 cells (bottom right) transiently transfected with 3’UTR FUS siRNA. Numbers below the blots refer to densitometry measurements of the experimental
condition (doxycycline-induced or transfected) relative to the untreated control condition for the respective cell line. SC refers to a scrambled (RNA) control sequence. Tubulin
serves as a loading control. (c) MTTanalyses revealed a decrease in cell viability upon FUS knockdown after 4 days compared with SC-expressing cells (left, shRNA in NSC-34
cells; middle, 3’UTR FUS siRNA in HEK-293T cells; right, 3’UTR FUS siRNA in NSC-34 cells). All conditions are reported as percent viability relative to untreated cells. Data
shown are the average of three independent experiments±S.E. Statistical significance was determined by a Student’s t-test (**Po0.01; NS, not significant). (d) Representative
immunofluorescence images demonstrating the degree of endogenous FUS (green) knockdown in NSC-34 cells induced to express shFUS1 versus transiently transfected with
3’UTR FUS siRNA for 4 days. Nuclei are stained with DAPI (blue). Arrow = detectable FUS knockdown, arrowhead = no detectable knockdown. Scale bar = 10 μm
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undergoing cell division and cell death.29 Overt cell death
(i.e., a large percentage of cells detaching from the culture
dish) was not observed upon FUS knockdown. Western blot
analyses confirmed that levels of the apoptosis markers
cleaved-PARP1 and cleaved-caspase-3 remained low and
unchanged throughout a 96 h FUS knockdown time course
(Figure 3a). Moreover, nuclear translocation of apoptosis-
inducing factor (AIF) was not observed upon FUS knockdown
at 24-h intervals (shown for 96 h in Figure 3b), ruling out
that apoptosis occurred through a caspase-independent
pathway.30
FUS knockdown results in impaired cell cycle progres-
sion. Time-lapse video microscopy was used to track the
fate of a single population of cells during FUS knockdown.
Imaging was initiated 24 h after shRNA induction and
continued for 3 days. Cell division occurred in shSC cells at
a normal frequency (Supplementary Video 1 and Figure 4a),
Figure 2 Decreased cell viability correlates with the degree of FUS knockdown. (a) NSC-34 cells expressing shFUS1 were uninduced, induced with tetracycline for 24 h after
which tetracycline was removed (induction + wash-out) or subjected to continuous induction and FUS knockdown. Western blot analyses of the indicated FUS knockdown
experiment reveal FUS expression is restored in the wash-out condition by day 6. Numbers below the blots refer to densitometry measurements that were normalized to ‘day 0’,
which represents the starting-point of the experiment. Tubulin serves as a loading control. (b) Quantification of cell number as a function of time for the indicated conditions. Cells
with continuous FUS knockdown exhibited the slowest growth rate between days 2 and 4 (inset) and throughout the 10-day experiment. Upon re-expression of FUS, the growth
rate for cells in the wash-out condition was accelerated and became similar to that of the uninduced condition. Data shown are the average of three independent experiments±S.E.
Statistical significance was determined by a Student’s t-test (*Po0.05; **Po0.01; ***Po0.001; day 6 significance is for the continuous induction condition). (c) Cell viability, as
determined by the MTT assay, correlates with the level of FUS protein expression, as determined by western/densitometry analyses. Data are compiled from three
independent FUS knockdown experiments, where shSC or shFUS1 was induced in NSC-34 cells for 1–5 days. An exponential fit of this data was created with GraphPad prism
(La Jolla, CA, USA)
Figure 3 Apoptosis is not activated during the cellular response to FUS knockdown. (a) Levels for apoptosis markers, cleaved-PARP1 and cleaved-caspase-3, do not change
with FUS knockdown as determined by western blot analyses of cell lysates derived from the indicated time points. As a positive control for apoptosis, NSC-34 cells were treated
with 1μM staurosporine (ST) for 2 h. Tubulin serves as a loading control. (b) Representative immunofluorescence images demonstrating localization of AIF (green) in NSC-34
cells. AIF translocates to the nucleus in cells treated with 100 μM ethacrinic acid (EA) for 8 h, but not upon shFUS1 induction for 96 h. Images are representative of two
independent experiments. Nuclei are stained with DAPI (blue). Scale bar = 10 μm
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whereas fewer cell division events were observed in shFUS
cells (Supplementary Video 2). Quantification of cell number
revealed a consistent ~ 1.7-fold increase in cell number every
24 h for control cells, whereas this change in cell number
decreased for shFUS cells (Figure 4b). Moreover, a 50%
reduction in EdU incorporation was observed in cells under-
going FUS knockdown for 96 h (Figures 4c and d). Together,
these data are consistent with a defect in cell proliferation.
Next, we sought to determinewhether a specific stage of the
cell cycle was impacted by FUS knockdown. Cell cycle
analysis by flow cytometry did not reveal a significant delay in
the various stages of the cell cycle (Figure 4e). However, cells
undergoing FUS knockdown for 96 h exhibited a robust and
significant increase in phosphorylated histone H3 (p-H3)
signal as assessed by immunofluorescence microscopy
(Figure 4f), indicative of mitotic arrest. In fact, the percentage
Figure 4 FUS knockdown results in impaired cell cycle progression. (a) Still frame images from time-lapse video microscopy obtained every 24h. One day after the induction
of shSC (top) or shFUS1 (bottom), cells were filmed using time-lapse microscopy for the duration of a 4-day knockdown. The average number of cells from three independent
counts of each image is indicated at the bottom right. Scale bar = 100 μm. (b) The change in cell number at 24-h time points relative to the previous time point, where ratios
41.0 are indicative of cell growth and ratioso1.0 of cell death. Data shown are the average of three independent counts of the still frame images + S.D. Statistical significance
was determined by a Student’s t-test (**Po0.01; ****Po0.0001). (c) Representative immunofluorescence images showing EdU incorporation (green) after 96 h of either shSC
(top) or shFUS1 (bottom) expression. Nuclei are stained with DAPI (blue). Scale bar = 50 μm. (d) Quantification of EdU immunofluorescence images revealed a 50% reduction
of EdU incorporation for cells expressing shFUS1 for 96 h as compared with cells expressing shSC. Data shown are the average of two independent experiments + S.E. Statistical
significance was determined by a Student’s t-test (*Po0.05). (e) Cell cycle analysis by flow cytometry following propidium iodide staining revealed no significant arrest at G1, S or
G2 after 96 h of shFUS1 expression in NSC-34 cells. Data shown are the average of seven independent experiments± S.E. (f) Representative immunofluorescence images
demonstrating p-H3 levels. After 96 h of shFUS1 expression in NSC-34 cells, p-H3 staining (green) is increased to levels comparable to treating cells with 1.6 μM nocodazole for
14 h to induce mitotic arrest. Cells expressing shSC for 96 h are similar to uninduced cells. Nuclei are stained with DAPI (blue). Scale bar = 50 μm. (g) Quantification of f shows a
significant increase in the percentage of p-H3-positive cells upon FUS knockdown or treatment with nocodazole (Noco). Data shown are the average of three independent
experiments±S.E. Statistical significance was determined by a one-way ANOVA and Tukey’s multiple comparisons test (**Po0.01; NS, not significant)
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of cells undergoing FUS knockdown for 96 h that were p-H3-
positive (~45%)was comparable to cells treatedwith nocodazole,
an inducer of mitotic arrest (Figure 4g). These data suggest
that a defect in mitosis is responsible for the overall reduction
in cellular proliferation upon FUS knockdown.
A phosphodiesterase-4 inhibitor, rolipram, partially
rescues the cell proliferation defect induced by FUS
knockdown. In addition to rescuing the proliferation defect
by re-expressing FUS (Figure 2), we sought to determine
whether small molecules could exert a similar protective
effect. To test this possibility, we screened a chemical library
consisting of 1086 small molecules, 606 of which were drugs
approved by the Food and Drug Administration (FDA) and
480 of which were purified natural products. Eight com-
pounds were initially identified (0.74% hit rate) that reversed
the proliferation defect and five-point dose-response curves
in the range of 0.1–30 μM were generated for each. After this
analysis, one compound, rolipram (Figure 5a), was found to
partially restore the 25% decrease in cell number induced by
FUS knockdown (Figure 5b). Rolipram is an inhibitor of
cAMP-specific phosphodiesterase-4 with antidepressant and
anti-inflammatory functions,31 including suppression of nitric
oxide production.32 The protective effect was less pro-
nounced at 30 μM, suggesting rolipram may exert toxicity at
higher doses. Rolipram also increased the cell number deficit
caused by shSC expression, however, this effect was modest
relative to shFUS1 cells and was not statistically significant
(Figure 5b). A western blot analysis demonstrated that the
protective effect of rolipram was not because of re-expression
of FUS (Figure 5c). These data suggest that rolipram or
related compounds could be further explored in the context of
therapeutics for disorders arising from a loss of FUS function.
Proteomic changes resulting from FUS knockdown.
Next, we sought to better understand the pathways involved
in the proliferation defect observed upon FUS depletion. To
this end, we performed quantitative proteomics using tandem
mass tags (TMTs) and mass spectrometry to assess
changes in the proteome after 24 and 96 h of FUS
knockdown.33,34 This approach allows for multiplexing of
multiple conditions within a single experiment and thus an
accurate comparison of protein levels between conditions.
Briefly, the N-termini of tryptically cleaved peptides are
labeled with isobaric mass tags. Each tag adds the same
molecular mass, but upon tandem mass spectrometry (MS/
MS) analysis, a unique reporter ion is detected for each
condition. The resulting reporter ion intensity directly corre-
lates to peptide abundance (Figure 6a). The 24-h time point is
expected to reflect an early response to FUS knockdown,
when FUS protein expression was reduced by only ~ 50%
(Figure 6b) and cell viability by only ~ 25% (Figure 2c). The
96-h time point was expected to reveal more robust changes
because the FUS knockdown phenotype is more severe
(Figures 1c and 6b) and this later time point allows for an
accumulation of protein expression changes, which depend
on the timescale of both protein translation and turnover.
Although it is standard to only compare cells with a specific
gene knocked down to cells expressing a scrambled RNA
sequence, we also included the uninduced condition in the
quantitative proteomics pipeline (Figure 6a) to ascertain
whether a particular protein changed in expression solely as
a consequence of FUS knockdown, or whether the process
of shRNA induction influenced the expression of that protein.
First, changes in the proteome arising from a loss of FUS
were assessed by comparing shFUS and shSC samples. A
total of 2355 proteins were quantified, with ~ 60% (1370
proteins) overlap between the three biological replicates
(Figure 6c). Only those proteins differentially expressed
between the shFUS and shSC samples by a fold change of
at least ± 0.25 in two of three replicates with a P-valueo0.05
were included in our final analysis. Sixty-one proteins, in
addition to FUS, met this criterion at either 24 or 96 h (Table 1).
Interestingly, 15 of these hits were previously identified as
RNA-binding targets of FUS, raising the possibility that these
expression changes stem from a loss of FUS function and/or
interaction with the corresponding transcripts (Table 1, aster-
isks).35–37 Of the 61 hits, 31 were various histone variants.
These were grouped into five main histone clusters (H1, H2A,
H2B, H3 and H4) because of the redundancy of the peptides
Figure 5 Rolipram partially rescues the cell proliferation defect induced by FUS knockdown. (a) Molecular structure of rolipram. (b) NSC-34 cells were induced to express
shSC or shFUS1 followed by the addition of rolipram at various concentrations (0–30 μM). After 4 days, cell number was quantified relative to uninduced controls by Hoechst
staining. In the absence of rolipram, cell number was reduced 25% for shFUS1 and 8% for shSC (n= 28 replicate wells from two independent experiments). This defect was
significantly reversed with 0.1–10 μM rolipram in shFUS1 cells (n= 20 replicate wells from two independent experiments; **Po0.01, ***Po0.001). To a lesser extent, rolipram
also recovered the deficit in shSC cells (n= 20 replicate wells from two independent experiments). Error bars represent + S.E. Statistical significance was determined by
comparing cells (shSC or shFUS1) treated with rolipram to the untreated (0 μM rolipram) condition using the Student’s t-test. (c) Western blot analysis of cell lysates
corresponding to the indicated conditions. FUS was knocked down only in cells induced with doxycycline to express shFUS1 and remained knocked down in the presence of 1μM
rolipram. Tubulin serves as a loading control
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used to identify each protein. Similarly, KAP0 and KAP1, the
regulatory subunits of protein kinase A, were counted as a
single hit because of a lack of unique peptides identified for
each protein. DAVID analysis (Database for Annotation,
Visualization, and Integrated Discovery) could not identify
significant enrichment of GO terms or functional categories for
the remaining 34 proteins, and therefore hits were assigned
categories manually based on information in UniProtKB, the
National Center for Biotechnology Information (NCBI) and
GeneCards (Figure 6d and Table 1). Chromatin organization
represented the most common category for proteins differen-
tially expressed at 24 h. Categories for which there were at
least four differentially expressed proteins at either 24 or 96 h
included cellular proliferation, kinases/phosphatases, cytos-
keletal organization, energy homeostasis, calcium-related and
metal ion binding. Of these, energy homeostasis, calcium-
related and metal ion binding were more prominent at 96 than
24 h, suggesting these changes are triggered by FUS knock-
down and become more pronounced with time.
Next, we validated protein hits that exhibited the largest
expression changes upon FUS knockdown, which were most
evident at 96 h. S100A6, also known as calcyclin because of
roles in both calcium binding and the cell cycle,38 exhibited a
relatively large decrease in expression in shFUS cells
compared with shSC cells at 96 h (Table 1). By comparing
both lines to the uninduced condition, it became apparent that
this difference is due in part to an increase in expression of
S100A6 in shSC cells (Supplementary Table 1). Differential
expression of S100A6 was validated by both western blot
(Figure 7a) and qPCR analyses at 96 h (Figure 7b) and qPCR
at 24 h (Figure 7c). Metallothionein-2 (MT2), a multifunctional
protein involved in zinc homeostasis and antioxidation,39
exhibited a large increase in expression in shFUS cells relative
to shSC cells at 96 h (Table 1). The differential expression of
MT2 in shFUS and shSC cells was validated by qPCR at 96 h
(Figure 7b) and 24 h (Figure 7c), however, this protein could
not be detected by western blot, presumably because of the
relatively small size of MT2 (6 kDa). The RNA-binding protein
EWS, which like FUS is a member of the TET family of
proteins, also increased in expression in shFUS cells (Table 1,
Figures 7b and 7d), as well as in HEK-293T cells transiently
transfected with si3’UTR for FUS knockdown (Figure 7d),
consistent with a previous report.40 This appears to be a
specific relationship between FUS and EWS expression as
FUS knockdown did not influence the expression of other
related RNA-binding proteins such as TDP43 and hnRNPA1,
or the other TET family member TAF15 (data not shown).
Similar to EWS, thymosin beta-10, a 5 kDa monomeric actin-
binding protein that inhibits actin polymerization,41 also
increased in expression upon FUS knockdown (Table 1 and
Figure 7b), but could not be detected by western blot.
Finally, we validated the differential expression of histones,
which decreased in expression by 20–65% after 24 h of FUS
knockdown but recovered by 96 h (Table 1). This difference
Figure 6 Quantification of the cellular proteome after FUS depletion. (a) Schematic of mass spectrometry pipeline. Briefly, NSC-34 cells were induced with doxycycline for 24
or 96 h to express either scrambled control shRNA (shSC) or shRNA targeting FUS (shFUS1). Uninduced cells were included as an additional control. Denatured lysates were
digested and the resulting peptides were labeled with unique isobaric mass tags (TMTs 126-131) and combined for mass spectrometry (MS) analysis. (b) Western blot analysis
confirmed FUS knockdown in lysates used for proteomics. Three biological replicates (BR 1, green; BR 2, blue; BR 3, red) were included. Tubulin serves as a loading control.
(c) A total of 2355 proteins were quantified by mass spectrometry over three biological replicates (BR 1–3). (d) Proteins differentially expressed between the shSC and shFUS1
samples by a fold change of at least ± 0.25 in two of three replicates were grouped into functional categories based on the literature (Table 1)
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arises from an increase in expression of histones in shSC cells
relative to both shFUS and uninduced cells (Supplementary
Table 1), which was validated by western blot analysis for
histones H2B and H3 (Figure 7e). Histones H2A and H4,
which were investigated based on availability of PCR primers,
were not significantly different between lines by qPCR
(Figure 7c) suggesting that the change in histone expression
predominately occurs at the protein level.
Discussion
Genetic alterations in FUS cause human diseases such as
cancer and neurodegeneration. In the study of sarcomas
caused by fusion of FUS with various transcription factors,
overexpression of the transcription factor component alone
was unable to promote tumor growth,42 suggesting that FUS is
essential for the oncogenic role of FUS-fusion proteins. A loss
of FUS function is implicated in the mechanisms associated
with various neurodegenerative disorders, however, the multi-
functional nature of FUS has made it difficult to discern which
of these functions is relevant to neurodegeneration.3 Further-
more, the effect of FUS knockdown or knockout in vivo has
produced conflicting results, as some reports describe animal
lethality,43–46 whereas others report no effect on survival.47–49
Consistent with the latter, signs of apoptosis or gross cellular
death were not observed here upon knockdown of FUS in
cultured mammalian cells (Figure 3). Rather, we demonstrate
for the first time that a reduction in FUS expression impairs cell
proliferation and progression through mitosis (Figures
1,2,3,4). Early studies of FUS knockout mice reported a
defect in meiosis, specifically within prophase,48 a step that
has common features in both meiosis and mitosis. This could
suggest FUS is required for progression of both mitosis and
meiosis through a common role in prophase.
To gain mechanistic insight into the correlation between
FUS expression and cell proliferation, we performed quanti-
tative proteomics on cells undergoing various degrees of FUS
knockdown, as no other study to date has performed a
comprehensive analysis of protein expression changes as a
function of FUS depletion. As one may expect, proteins
Table 1 Fold change and functional categories of proteins differentially expressed after 24 or 96 h of FUS knockdown in at least two of three biological replicates
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MT2 Metallothionein-2 ++ + ++ ++ +++ X
* MARCS Myristoylated alanine-rich C-kinase substrate + ++ ++ X X X
REEP2 Receptor expression-enhancing protein 2 + ++ +
ADT4 ADP/ATP translocase 4 + + X
* EWS RNA-binding protein EWS + + + + X X X
* U5S1 116 kDa U5 small nuclear ribonucleoprotein 
component + + X
TBAL3 Tubulin alpha chain-like 3 + + + X
* TOPK Lymphokine-activated killer T-cell-originated protein kinase + + X
FPPS Farnesyl pyrophosphate synthase + + + X X
CHSP1 Calcium-regulated heat stable protein 1 + ++ X X
KAD1 Adenylate kinase isoenzyme 1 + + X X
* SYAC Alanine--tRNA ligase, cytoplasmic + + X X
* IDHC Isocitrate dehydrogenase [NADP] cytoplasmic + + X X
FKB10 Peptidyl-prolyl cis-trans isomerase FKBP10 + + X X X
ENV2 Retrovirus-related Env polyprotein from Fv-4 locus + + X
* OSBP1 Oxysterol-binding protein 1 + + + X
ENV1 MLV-related proviral Env polyprotein + + X
* COX5A Cytochrome c oxidase subunit 5A, mitochondrial + + X X
TYB10 Thymosin beta-10 + + + X
* RAP1A Ras-related protein Rap-1A + + X X
RL29 60S ribosomal protein L29 + + + X
* TEBP Prostaglandin E synthase 3 + + + X X X X
* RBBP7 Histone-binding protein RBBP7 + + + + X X X
* ROA3 Heterogeneous nuclear ribonucleoprotein A3 + ++ X X
*
KAP0 / 
KAP1
cAMP-dependent protein kinase type I regulatory 
subunits alpha and beta + + ++ + + X X
PPBT Alkaline phosphatase, tissue-nonspecific isozyme + + ++ + X
* NPM Nucleophosmin + ++ + X X X X
S100A6 Protein S100-A6 + + ++ ++ + X X X X
* RRBP1 Ribosome-binding protein 1 + ++ X
H2A1 Histone H2A (H2A.J; type 1,1-F,H,K; 2-A,C; 3) + ++ + X
H14 Histone H1 (1.1-1.5; 1t) ++ ++ X
H2B1B Histone H2B (type 1-A,B,C/E/G, F/J/L,H,K,M,P; 2-B,E; 3-A,B) + +++ + X
H3C Histone H3 (3.1-3.3, 3.3C) + +++ X
H4 Histone H4 + +++ X
FUS RNA-binding protein FUS ++ ++ +++ +++ ++ ++ X X X
Fold-change -1.50 -1.25 -1.0 -0.75 -0.50 -0.25 0 0.25 0.50 0.75 1.0 1.25 1.50
Abbreviation: FC, fold change
Owing to a lack of unique peptides identified between histone variants, these hits were combined into the five major histone families (H1, H2A, H2B, H3 and H4).
Similarly, KAP0 and KAP1 were grouped because of a lack of unique peptides identified for each protein. Asterisks denote transcripts previously determined to be
bound by FUS
+ denotes FC between │0.25│ and │0.50│
++ denotes FC between │0.50│ and │1.0│
+++ denotes FC between4│1.0│
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associated with cell proliferation changed in expression upon
FUS knockdown (Figure 6d,Table 1). One of these proteins,
S100A6, exhibited reduced expression after 96 h (Figure 7,
Table 1), consistent with previous reports describing reduced
cell proliferation upon S100A6 knockdown.38,50 A role for FUS
in cell cycle has been described previously, as FUS inhibits
expression of the cell cycle protein cyclin D1 in response to
DNA damage signals51 and binds RNAs corresponding to cell
cycle genes.35
MT2 exhibited one of the largest changes in expression
between shFUS and shSC cells (Table 1). MT2 has a
protective role against metal toxicity, oxidative stress and
ionizing radiation. Accordingly, levels of MT2 increase in
response to these stressors.39,52 That expression of MT2 was
higher in shFUS cells relative to shSC cells at 24 h, a
difference that became more pronounced at 96 h (Figure 7,
Table 1), implicates a role for one of the aforementioned
stressors in the FUS knockdown-induced proliferation defect.
We speculate that oxidative stress may be the relevant
stressor, as FUS regulates the transcription of oxidative stress
protection genes and a loss of this function leads to elevated
ROS.53 In support of this notion, rolipram partially rescued the
proliferation defect upon FUS knockdown (Figure 5). Rolipram
has been shown to boost expression of antioxidizing
enzymes,54 suppress nitric oxide levels32,54 and exert a
protective effect in animal models of spinal cord injury55 and
neurodegeneration.56–58 Although the impact of rolipram on
cellular proliferation was strongest for shFUS cells, we note a
small effect on the control line that may signify a general effect
of rolipram on cell proliferation.59,60 Therefore, rolipram could
be further assessed in alternative models for loss of FUS
function.
Consistent with a previous report, we also detected an
increase in EWS expression upon FUS knockdown (Figure 7,
Table 1).40 EWS and FUS are both members of the TET family
of proteins and exhibit overlapping functions,1 raising the
intriguing possibility that increased EWS expression serves as
a compensatory mechanism for the loss of FUS function in
cells. An alternative, although not mutually exclusive, explana-
tion is that regulation of EWS at the RNA level is directly
impacted by FUS knockdown. In addition to EWS, 14 other hits
correspond to reported RNA-binding targets of FUS (Table 1,
asterisks).35–37 We posit that the protein expression changes
for these targets are a direct consequence of a loss of FUS
function with respect to RNA processing.
In agreement with previous studies, our proteomics analysis
revealed protein expression changes induced by doxycycline
and/or shRNA expression (i.e., proteins that changed in shSC
cells relative to uninduced cells; Supplementary Table 1).28,61,62
In fact, a recent study reported that expression of genes
involved in glycolysis and cellular metabolism were altered
upon doxycycline treatment.28 We also detected differential
expression for proteins associated with energy homeostasis
(FPPS, IDHC and KAD1) upon shSC induction at 96 h.
Intriguingly, these same changes were not detected in shFUS
cells (Supplementary Table 1). Thus, doxycycline exposure
and/or shRNA expression elicited changes in gene expres-
sion, but under conditions of FUS knockdown this response
was impaired. These results underscore the importance of
including an untreated control condition to assess the direction
of change for the experimental condition; without the untreated
condition we would have reported a decrease in histones for
shFUS cells at 24 h, when in fact there was an increase in
shSC and no response in shFUS cells (Supplementary
Table 1). The reason histones are increased in shSC cells at
24 h is unclear, however, the association of FUS with different
histone-related processes may explain the lack of response in
shFUS cells.35,51,63,64
The results of our study have important implications for
disease, particularly neurodegenerative disorders that may be
mediated through a loss of FUS function. Although mature
neurons are post mitotic and do not proliferate, the loss of FUS
function may adversely impact neurodevelopment during a
stage when cellular proliferation is critical. Moreover, the
processes and proteins that are altered here upon FUS
knockdown, particularly those relating to cytoskeletal organi-
zation, oxidative stress and calcium handling, are relevant to
the homeostasis of mature neurons.65 We also note that glia
cells, which do proliferate, have both neuroprotective and
pathogenic roles in neurodegeneration.66 That FUS is
aggregated and depleted from the nucleus of glia cells in
some neurodegenerative disorders23,67 raises the possibility
that glial proliferation and function may also be impaired.
Importantly, our data demonstrate it is possible to reverse the
adverse effects of FUS depletion by replacing the FUS protein
or by small-molecule intervention. Proteins that exhibit
differential expression upon FUS knockdown (Table 1) may
also serve as therapeutic targets for ameliorating the loss of
FUS function in disease.
Materials and Methods
Tissue culture. The creation of and culture conditions for NSC-34 cell lines
expressing shFUS1 or shSC have been described previously.2 The tetracycline-
inducible shFUS2 line was created and cultured in the same manner (shFUS2: 5′-
GAGTGGAGGTTATGGTCAA-3′). For the expression of shRNA, cells were treated
with 1 μg/ml doxycycline (Sigma-Aldrich (St. Louis, MI, USA), D9891) or 0.1 μg/ml
tetracycline (Fisher Scientific (Loughborough, England), BP912-100). Naive NSC-34
cells (a kind gift from Dr. Neil Cashman) were cultured in Dulbecco’s modified
Eagle’s medium with sodium pyruvate (Invitrogen (Grand Island, NY, USA), 10313)
supplemented with 10% fetal bovine serum (Sigma-Aldrich, F4135), 2 mM
L-glutamine (Invitrogen, 25030081) and 1% penicillin and streptomycin solution
(Invitrogen, 15140122). HEK-293T cells were maintained in minimum essential
media (Invitrogen, 10370) supplemented with 10% fetal bovine serum
(Sigma-Aldrich, F4135) and 1% penicillin and streptomycin solution (Invitrogen,
15140122).
siRNA knockdown of FUS. RNA oligonucleotides for FUS (sequences
below) and a scrambled control sequence (guide: 5′-AAUUCUCCGAACGUGUC
ACGU-3′; passenger: 5′-GUGACACGUUCGGAGAAUCUU-3′) were purchased
through Sigma-Aldrich and 10 μM annealed stocks were prepared by combining
guide and passenger strands in the following buffer: 100 mM potassium acetate,
30mM HEPES-KOH pH 7.4, 2 mM magnesium acetate. For knockdown in
HEK-293T cells, cells were plated in a 24-well plate at 2000 cells per well and
allowed to adhere overnight. Transfection was performed in OPTI-MEM (Invitrogen,
31985070) using 0.4 μl Lipofectamine RNAiMax (Invitrogen, 13778030) and
0.2 nM siRNA per well (guide: 5′-UUGGGUGAUCAGGAAUUGGAA-3′; passenger:
5′-CCAAUUCCUGAUCACCCACUU-3′). For knockdown in naive NSC-34 cells,
cells were plated in a 24-well plate at 10 000 cells per well. Transfection was
performed as above, but with 0.5 μl RNAiMax and 10 nM siRNA per well (guide:
5′-UAGGGUAGUCUGACACACACA-3′; passenger: 5′-UGUGUGUCAGACUACC
CUCUU-3′).
MTT viability assay. Cells were plated in technical triplicate in a 24-well plate
and induced to express shRNA or transfected with siRNA to initiate FUS
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knockdown. After the desired duration of knockdown, the media from each well was
removed and replaced with 400 μl fresh media and 100 μl of 5 mg/ml MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide; Invitrogen, M-6494). After a
35-min incubation at 37 ºC, 300 μl lysis buffer (10% SDS in 1:1 N,N-
dimethylformamide:water/2% acetic acid/2.5% HCl 1M)68 was added to each well.
Plates were covered with a seal and incubated at 37 °C overnight followed by OD
quantification at 550 nm. Results are expressed as % cell viability relative to
untreated controls using the following equation: 100 × (ODRNAi–ODblank)/(ODuntreated
– ODblank). The ODblank was determined by wells containing MTT and tissue culture
media without cells.
Immunofluorescence. Cells grown on glass coverslips were fixed for
5–10 min with 4% paraformaldehyde and blocked with PBSAT (1X phosphate-buffered
saline (PBS)/1% BSA/0.5% Triton-X 100) for 30–60 min at room temperature.
Primary antibodies were diluted in PBSAT and added to the coverslips at room
temperature for 1 h. Primary antibody dilutions were as follows: 1 : 500 for anti-FUS
(Bethyl laboratories (Montgomery, TX, USA), A300-293A), 1 : 100 for anti-AIF (Cell
Signaling (Danvers, MA, USA), 4642) and 1 : 250 for p-H3 (Santa Cruz
Biotechnology (Santa Cruz, CA, USA), sc-8656-R). After primary antibody
incubation, coverslips were washed with PBSAT and incubated for 45 min with
Alexa Fluor 488-conjugated donkey anti-rabbit IgG (Jackson ImmunoResearch Labs
(West Grove, PA USA), 711-545-152), diluted at 1 : 2000 in PBSAT. Finally, cells
were stained with 34`ng/ml DAPI and coverslips were mounted with ProLong Gold
anti-fade reagent (Invitrogen, P36930). The percentage of cells positive for p-H3
was determined with MetaMorph V7.6.3 software (Molecular Devices, Sunnyvale,
CA, USA) using the Multi Wavelength Cell Scoring application. Briefly, immuno-
fluorescence images were opened in MetaMorph and using the application, cells were
identified by DAPI staining and scored for p-H3 based on a 488 nm intensity of 1000
gray levels above background. The number of cells positive for p-H3 was divided by the
total number of cells identified by DAPI staining to determine a percentage.
Western blotting. Cells were lysed for 30 min at 4 °C with either 50 mM Tris
HCl (pH 7.5) containing 0.5 M NaCl, 1% NP-40, 1% deoxycholic acid, 0.1% SDS
and 2 mM EDTA or RIPA buffer (Boston BioProducts (Ashland, MA, USA), BP-115-
500), supplemented with protease (Roche (Basel, Switzerland), 11836170001) and
phosphatase (Roche, 4906837001) inhibitors. Concentration of cell lysates was
determined using a bicinchoninic acid (BCA) assay (Thermo Scientific Pierce
(Rockford, IL, USA), 23227) and samples were prepared in Laemmli SDS-sample
buffer (Boston BioProducts, BP-111R). Standard western blotting procedures were
followed using Tris-glycine SDS-PAGE and electrotransfer onto PVDF membrane at
100 V for 1 h at 4 ºC. For detection of S100A6, Tris-tricine SDS-PAGE was used
(Bio-Rad (Hercules, CA, USA), 456-3066) followed by electrotransfer onto 0.22 μm
nitrocellulose at 100 V for 30 min at 4 ºC. Membranes were blocked for 1 h at room
temperature with Odyssey Blocking Buffer (LiCor (Lincoln, NE, USA), 927–40003)
diluted 1 : 1 with PBS containing 0.1% Tween-20 (PBST), followed by overnight
incubation at 4 °C with primary antibodies diluted in PBST. Primary antibody
dilutions were as follows: 1:500 anti-FUS (Genscript (Piscataway Township, NJ,
USA), generated against C-terminal peptide CKFGGPRDQGSRHDSEQ
DNSD)2, 1:500 anti-tubulin (Sigma (St. Louis, MO, USA), T9026), 1 : 500 anti-
cleaved PARP1 (Cell Signaling, 9544), 1 : 500 anti-cleaved caspase-3 (Cell
Signaling, 9664), 1 : 500 anti-EWS (Santa Cruz Biotechnology, sc-28327), 1 : 1000
anti-H2B (Active motif, Carlsbad, CA, USA), 1 : 1000 anti-H3 (Abcam (Cambridge,
England), 1791) and 1 : 200 anti-S100A6 (Cell Signaling, 13162). Following primary
antibody incubation, membranes were washed with PBST and incubated for 1h with
secondary antibody diluted 1 : 10 000 in 1:1 Odyssey Blocking Buffer:PBST.
Secondary antibodies included anti-mouse IRDye 680 (LiCor, 926-68072) or IRDye
800 (LiCor, 926-32210) and anti-rabbit IRDye 680 (LiCor, 926-68023) or IRDye 800
Figure 7 Western and qRT-PCR validation of proteins differentially expressed upon FUS depletion. (a) Western blot analysis of lysates from uninduced NSC-34 cells (–) and
cells induced to express scrambled control shRNA (S) or shRNA targeting FUS (F) for 96 h. Numbers below the blots refer to densitometry measurements relative to uninduced
cells and demonstrate increased expression of S100A6 in shSC cells with a concomitant decrease in shFUS1 cells. Tubulin serves as a loading control. (b and c) qRT-PCR
analysis after 96 h (b) or 24 h (c) of shRNA induction. RNA expression relative to uninduced cells was determined for the indicated genes after shSC or shFUS1 induction in
NSC-34 cells. Data shown are the average of three independent experiments + S.E. Statistical significance was determined by a Student’s t-test (*Po0.05; **Po0.01;
***Po0.001). (d) Representative western blot analysis of lysates from NSC-34 cells or HEK-293T cells after 96 h demonstrating increased expression of EWS with FUS
knockdown relative to controls. (e) Representative western blot analysis of lysates from NSC-34 cells induced to express shRNA for 24 h demonstrating increased histone
expression in shSC cells with a concomitant decrease in shFUS1 cells
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(LiCor, 926-32211). After washing with PBST, membranes were imaged with an
Odyssey Infrared Imager (LiCor, Model 9120) and protein band intensities were
quantified with the Odyssey Software (LiCor, V3.0).
Time-lapse video microscopy. Stable NSC-34 cells were plated on glass
coverslips and induced to express either shSC or shFUS1. Twenty-four hours later,
coverslips were assembled into chambers as previously described69 and imaged at
37 °C with BH2 (Olympus, Center Valley, PA, USA) microscopes equipped with
phase-contrast optics using 10X objectives/0.3–0.32 NA. Image sequences were
gathered using Retiga EX (Qimaging, Corp., Surrey, Canada) or Retiga EXi Fast
(Qimaging, Corp.) cameras. Images were acquired every 3 min with C-imaging
software (Hamamatsu Photonics, Hamamatsu City, Japan) and were exported as
QuickTime videos using CinePak compression (Apple, Cupertino, CA, USA).
EdU incorporation. NSC-34 cells were plated on glass coverslips at 10 000
cells per well and induced 12–16 h later to express shSC or shFUS. After 96 h of
induction, cells were exposed to 10 μM EdU for 30 min and processed according to
manufacturer’s instructions (Click-iT EdU Alexa Fluor 488 Imaging Kit, Life
Technologies (Carlsbad, CA, USA), C10337). The percentage of cells positive for
EdU was determined with MetaMorph V7.6.3 software using the Multi Wavelength
Cell Scoring application. Briefly, immunofluorescence images were opened in
MetaMorph and using the application, cells were identified by DAPI staining and
scored for EdU incorporation based on a 488 nm intensity of 1000 gray levels above
background. The number of cells positive for EdU was divided by the total number
of cells identified by DAPI staining to determine a percentage.
Cell cycle analysis. Following 96 h of shRNA induction in NSC-34 cells,
~ 2E10+6 cells were collected in 100 μl PBS, fixed by the dropwise addition of
900 μl of cold (−20 ºC) 95% ethanol while vortexing gently, and stored at 4 °C
overnight. Following the overnight fixation, the ethanol was removed by pelleting the
cells and washing with PBS. One milliliter of staining solution (900 μl PBS+2 mM
MgCl2, 50 μl propidium iodide stock solution (1 mg/ml, Sigma, P4170), 50 μl RNase
stock solution) was then added to the cells and incubated in the dark at 37 °C for
20 min, followed by analysis within a few hours using a FACSCalibur platform
(BD Biosciences, San Jose, CA, USA).
Small-molecule high-content screen. For the high-content screen,
shFUS1 NSC-34 cells were plated onto 384-well plates (Corning (Corning, NY,
USA) 3712) at 500 cells per well in 40 μl of culture media (described above) using a
Multidrop automated liquid handler (Thermo Fisher Scientific, Waltham, MA, USA).
Gas-permeable seals were used to reduce any uneven evaporation effects. After
overnight incubation, 5 μl doxycycline was transferred using a Biomek NX robotic
liquid handler (Beckman Coulter, Indianapolis, IN, USA) into each experimental well
to attain a final concentration of 1 μg/ml. An equal volume of doxycycline solvent (dd
H2O) was added to control wells. Four hours after doxycycline addition, 5 μl of
compounds from the Laboratory for Drug Discovery in Neurodegeneration (LDDN)
library (described below) were transferred using the robotic liquid handler into
experimental wells to attain a final concentration of 1 μM and 0.1% DMSO. An equal
volume of DMSO in media was added to control wells. Plates were incubated for
96 h. Screening of compounds was performed in triplicate because of the small
activity window (25%) as determined during assay development using this format.
A subset of the LDDN chemical library was used, consisting of 606 compounds
approved by the FDA (Prestwick, France) and 480 purified natural products.
Compounds for high-throughput screening were stored as DMSO stocks at − 20 °C
and assay-ready 384-well plates with 1.67 mM compound concentration in 100%
DMSO were diluted in media to attain a final concentration of 1 μM in 0.1% DMSO
just before use.
After 96 h, cells were fixed with 4% paraformaldehyde for 20 min and washed three
times with PBS (ELx405 plate washer, BioTek (Winooski, VT, USA)). The cells were
labeled with 1 μg/ml Hoechst stain to visualize nuclei. Images were captured on the
IN Cell Analyzer 2000 (GE Healthcare, Pittsburgh, PA, USA). The entire well was
imaged in four fields at 25-ms exposure time using excitation filter D360/40 and
emissions filter HQ460/40 in combination with a 10X/0.45 NA objective. Image stacks
were batched and analyzed using IN Cell Workstation software (GE Healthcare). For
the feature extraction protocol, cells were segmented using the multi-target analysis
algorithm and nuclei were segmented as defined with a minimum area of 50 μm2 with
a sensitivity setting of 70. Total nuclei per well was used as a measure of cell count. In
converting this assay from a 24-well to a 384-well format, the effect of FUS
knockdown on cell viability was reduced from ~ 40 to ~ 25%, perhaps because of the
reduced plate format and cell plating. This small signal window was a challenge for
high-throughput screening and therefore compounds were screened in triplicate.
A compound was considered a 'hit' and selected for confirmation if it rescued the
shFUS1 knockdown-induced decrease in cell number by43 S.D. from the mean of
the shFUS1 knockdown control wells (shFUS1 +doxycycline) on each of the three
replicate plates. Hits were confirmed via a five-point dose-response curve
(0.1–30 μM) using compounds that were re-ordered from the commercial suppliers.
For confirmation studies, compounds were added to both shSC and shFUS1-
expressing cells in the presence of doxycycline. Western blot analysis of FUS
expression after 96 h of 1 μM compound incubation was performed using a similar
protocol to that described above.
Quantitative proteomics. NSC-34 cells were either uninduced, or induced to
express shSC or shFUS1 for 24 or 96 h (for a total of six samples), followed by lysis
with RIPA buffer (Boston BioProducts, BP-115-500) supplemented with protease
inhibitors (Roche, 11836170001). Protein content was measured using a standard
BCA Assay (Thermo Scientific, Waltham, MA, USA) and lysates were treated
according to manufacturer's instructions, with slight method alteration in the
detergent removal step. Briefly, 100 μg of lysate was diluted to a final concentration
of 1 μg/μl with 100 mM triethyl ammonium bicarbonate. Disulfide bonds were
reduced with 0.5 M tris(2-carboxyethyl)phosphine for 1 h at 55 °C and cysteine
residues were alkylated with 375 mM iodoacetamide for 30 min at ambient
temperature, protected from light. Lysates were then treated for detergent clean up
using Detergent Removal Spin Columns (Thermo Scientific) according to
manufacturer's instructions and digested overnight at 37 °C with Trypsin (Promega
(Madison, WI, USA), sequencing grade) in a 1 : 25 (w/w) enzyme:protein digest
ratio. Amine reactive TMT reagents (Thermo Scientific, 6-plex kit) were dissolved in
acetonitrile and allowed to react with peptides for 1 h at ambient temperature. After
1 h, the reaction was quenched upon addition of 5% hydroxylamine hydrochloride
followed by a 15-min incubation at room temperature. Following labeling, the
samples were combined in an equi-volume ratio (1 : 1 : 1 : 1 : 1 : 1) and dried down
before reconstitution in 5% acetonitrile, 0.1% trifluoroacetic acid for mass spectrometric
analysis. The assignment of TMT tag (126–131) to each sample was randomized
(www.random.org) to guard against bias. Assignments were made such that no sample
had the same tag identity between three independent experiments.
Three independent experiments (biological replicates) were tested, with each
experiment analyzed in technical triplicate. LC-MS/MS experiments were performed
on a QExactive hybrid mass spectrometer (Thermo Scientific) equipped with a
nanoAcquity UPLC (Waters, Milford, MA, USA). Briefly, approximately 1 μg of labeled
peptides were loaded on a 100 μm i.d. fused-silica precolumn packed with 2 cm of
Magic C18AQ resin (5 μm, 200 Å, Michrom Bioresources, Auburn, CA, USA) at a flow
rate of 4.0 μl/min for 4 min in 5% acetonitrile, 0.1% formic acid (FA) and eluted using a
gradient at 300 nl/min onto a 75 μm i.d. analytical column packed with 25 cm of Magic
C18AQ resin (3 μm, 100 Å, Michrom Bioresources) to a gravity-pulled tip. Separation
was achieved by applying a 5–35% acetonitrile gradient in 0.1% FA over 180 min at
300 nl/min. In detail, the time program was: 0− 180 min, 5− 35% B; 180− 181 min,
35–90% B; 181–191 min, 90% B; 191–192 min, 90-5% B; 192–210 min, 5% B;
210 min, stop. Solvent A was water with 0.1% FA and solvent B was acetonitrile with
0.1% FA. Electrospray ionization was enabled via liquid junction into a QExactive
hybrid mass spectrometer (Thermo Scientific). Instrument conditions closely matched
those of the ‘sensitive’ conditions previously recommended.70 Mass spectra were
acquired over m/z 300–1750 at 70 000 resolution (m/z 200) and data-dependent
acquisition selected the top 12 most abundant precursor ions for MS/MS by HCD
fragmentation using an isolation width of 1.2 m/z, normalized collision energy of 30%
and a resolution of 35 000.
Mass spectra were submitted to MASCOT (Matrix Science (Boston, MA, USA),
v2.4.1) and searched against a parsed mus musculus database (SwissProt, July
2013, containing 16 627 entries). Search specifications considered up to two missed
cleavage sites, full tryptic specificity, precursor mass tolerance of 10 p.p.m. and a
fragment ion tolerance of 0.05 Da. Specified fixed modifications include carbamido-
methylation (Cys) and TMT6plex were considered as fixed modifications, whereas
pyroglutamylation (Gln), oxidation (Met) and acetylation (N-terminus) were
considered as variable modifications.
Raw files and Mascot search results were uploaded to ProteoIQ (Premier Biosoft
(Palo Alto, CA, USA), v2.6.03) for quantitation based upon reporter ion signal intensity
(m/z 126–131). The normalized reporter ion intensity was determined from the sum of
reporter ions intensities across all experimental conditions and technical replicates for
each peptide. Normalized ion intensities were then applied to each individual reporter
ion for each peptide and weighted by the corresponding peptide precursor ion
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intensity. The quantitation values of each individual reporter ion from all peptides
within a protein were then averaged to yield an overall protein quantitation value for
each experimental condition. Quantification parameters included: reporter ion
tolerance – 0.05 Da; minimum peptide length – 6 amino acids; minimum # of spectra
– 2; minimum # of peptides – 2; minimum peptide probability – 0.05; minimum protein
probability – 0.5 and data centroided. After protein set generation, data were further
filtered for statistical significance with the following stringencies: P-value ≤ 0.05 and
fold change ≥ | 0.25 |.
Quantitative real-time PCR (qRT-PCR). RNA was harvested from cells
(Bio-Rad, 732-6820) and converted to cDNA (Bio-Rad, 170-8841), according to the
manufacturer’s instructions. qRT-PCR was performed in technical triplicate using
PrimePCR primer assays (Bio-Rad, 100-25636) and SYBR Green Supermix
(Bio-Rad, 172-5121) according to manufacturer’s guidelines and using the following
PCR program in a CFX384 Touch Real-Time PCR Detection System (Bio-Rad):
95 °C for 2 min, 40 cycles of 95 °C for 5 s and 60 °C for 30 s, and a melt-curve of
65–95 °C (0.5 °C increments per 5 s). Quantification of differential mRNA
expression was calculated by the comparative Ct method using Bio-Rad CFX
Manger 3.1 software. Briefly, threshold cycle (Ct) values were normalized to the
B2M reference gene Ct value to obtain ΔCt values. The ΔCt value for the control
condition was subtracted from the ΔCt of the experimental condition to calculate a
ΔΔCt. Fold change relative to the control samples was then calculated by 2-(ΔΔCt).
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